Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOC-MEK: Docetaxel +/- Selumetinib in wt BRAF Melanoma
NCT01256359Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Oct 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in melanoma, sponsored by University of Oxford. Started Oct 2010; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01256359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256359.